Efficacy and Security of Zoledronic Acid for Remedy of Postmenopausal Osteoporosis: A Meta-Evaluation of Randomized Managed Trials.
Am J Ther. 2017 Sep/Oct;24(5):e544-e552
Authors: Wang C
We carried out a meta-analysis primarily based on eligible research to evaluate the efficacy and security of zoledronic acid therapy for postmenopausal girls with osteoporosis. PubMed, Net of Science, and Embase have been looked for eligible research that assessed the efficacy of zoledronic acid within the prevention of fractures amongst postmenopausal girls with osteoporosis. The first outcomes have been new vertebral fracture, nonvertebral fracture, and hip fracture. Secondary outcomes have been bone mineral density (BMD) and security outcomes. A set-effect or random-effect mannequin was used to pool the estimates in keeping with the heterogeneity among the many included research. Eight randomized managed trials, involving 13,335 sufferers, have been included on this meta-analysis. Pooled outcomes confirmed that therapy with zoledronic acid considerably lowered the incidences of nonvertebral fractures, vertebral fractures, and hip fractures, as in contrast with placebo. Zoledronic acid was additionally related to important enchancment in BMD at lumbar backbone, complete hip, femoral neck, and trochanter. Nonetheless, the incidence of any hostile occasions was greater within the zoledronic acid group than that within the management group, and critical hostile occasions have been comparable between the two teams. This meta-analysis indicated that zoledronic acid might considerably cut back the fracture danger and enhance BMD in postmenopausal girls with osteoporosis. Moreover, it could not lead to critical hostile occasions. Zoledronic acid could possibly be used as an efficient and well-tolerated therapy for postmenopausal girls with osteoporosis.
PMID: 26938765 [PubMed – indexed for MEDLINE]